-
1
-
-
0026668010
-
A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality
-
Bromidge, S.M., Brown, F., Cassidy, F., Clark, M.S.G., Dabbs, S., Hawkins, J., Loudon, J.M., Orlek, B.S., Riley, G.J. A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality. Bioorg Med Chem Lett 1992, 2: 791-6.
-
(1992)
Bioorg Med Chem Lett
, vol.2
, pp. 791-796
-
-
Bromidge, S.M.1
Brown, F.2
Cassidy, F.3
Clark, M.S.G.4
Dabbs, S.5
Hawkins, J.6
Loudon, J.M.7
Orlek, B.S.8
Riley, G.J.9
-
2
-
-
0028102239
-
Synthesis and properties of [R-(Z)]-(+)-α-(1-azabicyclo[2.2.2]oct-3-yl)-α-(methoxyimino) acetonitrile, a novel functionally selective muscarinic partial agonist
-
Bromidge, S.M., Cassidy, F., Clark, M.S.G., Eggleston, D.S., Oriek, B.S. Synthesis and properties of [R-(Z)]-(+)-α-(1-azabicyclo[2.2.2]oct-3-yl)-α-(methoxyimino) acetonitrile, a novel functionally selective muscarinic partial agonist. J Chem Soc Chem Commun 1994, 18: 2189-90.
-
(1994)
J Chem Soc Chem Commun
, vol.18
, pp. 2189-2190
-
-
Bromidge, S.M.1
Cassidy, F.2
Clark, M.S.G.3
Eggleston, D.S.4
Oriek, B.S.5
-
3
-
-
2642672623
-
-
AU 9053159, EP 392803, JP 91007285, JP 97188678, JP 97188679, US 5278170
-
Orlek, B.S., Bromidge, S.M., Dabbs, S. (Beecham Group plc). Novel cpds. AU 9053159, EP 392803, JP 91007285, JP 97188678, JP 97188679, US 5278170.
-
Novel Cpds
-
-
Orlek, B.S.1
Bromidge, S.M.2
Dabbs, S.3
-
4
-
-
2642648474
-
-
WO 9531456
-
Bromidge, S.M., Voyle, M., Faruk, E.A., Hughes, M.J., Kitteringham, J., Borret, G.T. (SmithKline Beecham plc). Process for the preparation of azabicyclic derivs. WO 9531456.
-
Process for the Preparation of Azabicyclic Derivs
-
-
Bromidge, S.M.1
Voyle, M.2
Faruk, E.A.3
Hughes, M.J.4
Kitteringham, J.5
Borret, G.T.6
-
5
-
-
2642681457
-
-
EP 759920, US 5675007, WO 9531457
-
Keogh, J., Borrett, G.T., Bromidge, S.M., Faruk, E.A., Hughes, M.J., Kitteringham, J., Voyle, M. (SmithKline Beecham plc). Derivs. of quinuclidine N-oxide as muscarinic receptor ligands. EP 759920, US 5675007, WO 9531457.
-
Derivs. of Quinuclidine N-oxide as Muscarinic Receptor Ligands
-
-
Keogh, J.1
Borrett, G.T.2
Bromidge, S.M.3
Faruk, E.A.4
Hughes, M.J.5
Kitteringham, J.6
Voyle, M.7
-
8
-
-
0028210934
-
1,2,5,6-Tetrahydropyridine oxime ethers incorporating electron withdrawing groups are potent and selective muscarinic agonists
-
Bromidge, S.M., Brown, F., Cassidy, F., Clark, M.S.G., Collings, E.J., Dabbs, S., Faulkner, R.E., Loudon, J.M., Orlek, B.S., Riley, G.J. 1,2,5,6-Tetrahydropyridine oxime ethers incorporating electron withdrawing groups are potent and selective muscarinic agonists. Bioorg Med Chem Lett 1994, 4: 557-62.
-
(1994)
Bioorg Med Chem Lett
, vol.4
, pp. 557-562
-
-
Bromidge, S.M.1
Brown, F.2
Cassidy, F.3
Clark, M.S.G.4
Collings, E.J.5
Dabbs, S.6
Faulkner, R.E.7
Loudon, J.M.8
Orlek, B.S.9
Riley, G.J.10
-
9
-
-
2642612626
-
1 receptors
-
(July 24-29, Osaka) Abst 646
-
1 receptors. 5th Int Conf Alzheimer's Dis Relat Disord (July 24-29, Osaka) 1996, Abst 646.
-
(1996)
5th Int Conf Alzheimer's Dis Relat Disord
-
-
Clark, M.S.G.1
Brown, F.2
Harries, M.3
Hatcher, J.4
Hawkins, J.5
Loudon, J.M.6
Noy, G.7
Riley, G.8
-
12
-
-
2642610088
-
1 receptors
-
(April 10-14, Nice) Abst 60
-
1 receptors. 4th Int Nice/Springfield Symp Advances Alzheimer Ther (April 10-14, Nice) 1996, Abst 60.
-
(1996)
4th Int Nice/Springfield Symp Advances Alzheimer Ther
-
-
Loudon, J.1
Clark, M.2
Brown, F.3
Bromidge, S.4
Harries, M.5
Hawkins, J.6
Hatcher, J.7
Noy, G.8
Riley, G.9
-
14
-
-
2642638551
-
Single & repeat dose kinetics of SB 202026 in young and elderly volunteers
-
(April 10-14, Nice) Abst 99
-
Zussman, B., Davie, C., Cyronak, M., Kumar, R., Cooper, S. Single & repeat dose kinetics of SB 202026 in young and elderly volunteers. 4th Int Nice/Springfield Symp Advances Alzheimer Ther (April 10-14, Nice) 1996, Abst 99.
-
(1996)
4th Int Nice/Springfield Symp Advances Alzheimer Ther
-
-
Zussman, B.1
Davie, C.2
Cyronak, M.3
Kumar, R.4
Cooper, S.5
-
15
-
-
2642644384
-
Effect of food coadministration on tolerability and kinetics of SB 202026
-
(April 10-14, Nice) Abst 22
-
Cooper, S., Kumar, R., Higgins, R., Zussman, B., Davie, C., Cyronak, M. Effect of food coadministration on tolerability and kinetics of SB 202026. 4th Int Nice/Springfield Symp Advances Alzheimer Ther (April 10-14, Nice) 1996, Abst 22.
-
(1996)
4th Int Nice/Springfield Symp Advances Alzheimer Ther
-
-
Cooper, S.1
Kumar, R.2
Higgins, R.3
Zussman, B.4
Davie, C.5
Cyronak, M.6
-
16
-
-
2642650155
-
Safety and tolerability of SB 202026 in young and elderly volunteers
-
(April 10-14, Nice) Abst 51
-
Kumar, R., Cooper, S. Safety and tolerability of SB 202026 in young and elderly volunteers. 4th Int Nice/Springfield Symp Advances Alzheimer Ther (April 10-14, Nice) 1996, Abst 51.
-
(1996)
4th Int Nice/Springfield Symp Advances Alzheimer Ther
-
-
Kumar, R.1
Cooper, S.2
-
17
-
-
2642606814
-
Safety, tolerability and pharmacokinetics of SB 202026 in man
-
(July 24-29, Osaka) Abst 119
-
Cooper, S., Kumar, R., Higgins, R., Zussman, B., Davie, C., Cyronak, M. Safety, tolerability and pharmacokinetics of SB 202026 in man. 5th Int Conf Alzheimer's Dis Relat Disord (July 24-29, Osaka) 1996, Abst 119.
-
(1996)
5th Int Conf Alzheimer's Dis Relat Disord
-
-
Cooper, S.1
Kumar, R.2
Higgins, R.3
Zussman, B.4
Davie, C.5
Cyronak, M.6
-
18
-
-
2642610896
-
Efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer's disease
-
(July 24-29, Osaka) Abst 647
-
Kumar, R., Orgogozo, J. Efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer's disease. 5th Int Conf Alzheimer's Dis Relat Disord (July 24-29, Osaka) 1996, Abst 647.
-
(1996)
5th Int Conf Alzheimer's Dis Relat Disord
-
-
Kumar, R.1
Orgogozo, J.2
-
19
-
-
0009709566
-
Efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer's disease
-
K. Iqbal, B. Winblad, T. Nishimura, M. Takeda and H.M. Wisniewski (Eds.), John Wiley & Sons Ltd., Chichester
-
Kumar, R., Orgogozo, J. Efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer's disease. In: Alzheimer's Disease: Biology, Diagnosis and Therapeutics, K. Iqbal, B. Winblad, T. Nishimura, M. Takeda and H.M. Wisniewski (Eds.), John Wiley & Sons Ltd., Chichester, 1997, 677-85.
-
(1997)
Alzheimer's Disease: Biology, Diagnosis and Therapeutics
, pp. 677-685
-
-
Kumar, R.1
Orgogozo, J.2
-
20
-
-
2642651720
-
-
SmithKline Beecham Company Communication December 1
-
SmithKline Beecham Company Communication December 1, 1997.
-
(1997)
-
-
-
21
-
-
2642650154
-
Muscarinic partial agonists in the symptomatic treatment of Alzheimer's disease
-
Abst S-14-2
-
Kumar, R., Cedar, E., Clark, M., Loudon, J., McCafferty, J., Hammond, L. Muscarinic partial agonists in the symptomatic treatment of Alzheimer's disease. Eur Neuropsychopharmacol 1996, 6(Suppl. 3): Abst S-14-2.
-
(1996)
Eur Neuropsychopharmacol
, vol.6
, Issue.3 SUPPL.
-
-
Kumar, R.1
Cedar, E.2
Clark, M.3
Loudon, J.4
McCafferty, J.5
Hammond, L.6
-
22
-
-
2642615199
-
Muscarinic partial agonists in the symptomatic treatment of Alzheimer's disease
-
(April 10-14, Nice)
-
Kumar, R., Cedar, E., Clark, M., Loudon, J., McCafferty, J. Muscarinic partial agonists in the symptomatic treatment of Alzheimer's disease. 4th Int Nice/Springfield Symp Advances Alzheimer Ther (April 10-14, Nice) 1996, 73.
-
(1996)
4th Int Nice/Springfield Symp Advances Alzheimer Ther
, pp. 73
-
-
Kumar, R.1
Cedar, E.2
Clark, M.3
Loudon, J.4
McCafferty, J.5
-
23
-
-
2642679054
-
Differential pulse polarographic determination of [R-(Z)]-α-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitrile monohydrochloride in tablets following derivatization with dimethyldioxirane
-
Ennis, J.N., Buxton, P.C. Differential pulse polarographic determination of [R-(Z)]-α-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitrile monohydrochloride in tablets following derivatization with dimethyldioxirane. Anal Commun 1996, 33: 261-3.
-
(1996)
Anal Commun
, vol.33
, pp. 261-263
-
-
Ennis, J.N.1
Buxton, P.C.2
-
24
-
-
2642708183
-
-
WO 9704750
-
Napper, J.A., Mortimer, N., O'Brien, K.T., Manek, S.J., Kumar, R., Clark, M.S.G., Loudon, J.M. (SmithKline Beecham plc). Process for preparing solid dosage forms of very low-dose drugs. WO 9704750.
-
Process for Preparing Solid Dosage Forms of Very Low-dose Drugs
-
-
Napper, J.A.1
Mortimer, N.2
O'Brien, K.T.3
Manek, S.J.4
Kumar, R.5
Clark, M.S.G.6
Loudon, J.M.7
|